Epidural Platelet Rich Plasma Injection for Herpes Zoster

NCT05538364 | Unknown

• 1 other identifier: UW22-518
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Herpes zoster is a common disease, usually caused by the reactivation of latent varicella zoster virus from the dorsal root ganglion. Acute herpes zoster is characterized by severe pain and the appearance of vesicular skin rashes that usually heal in 2-3 weeks. One of the complications of acute herpes zoster is post-herpetic neuralgia (PHN), which is usually defined as persistent pain lasing 90 days or more from the onset of skin rash. The reported incidence of PHN ranges from between 5% to over 50%. PHN can negatively impact one's quality of life due to serious physical, psychological, functional, and social disturbances due to consequences of chronic pain. Platelet rich plasma (PRP) is an emerging treatment option for chronic pain. It is currently used predominantly for treating musculoskeletal pain conditions such as osteoarthritis and tendinopathies. However, PRP promotes the healing of nerve injury and reduces neuropathic pain, making it a potentially promising treatment option for neuropathic pain. The effect of interlaminar epidural PRP for PHN has not been studied. In this study, a case series will be performed to investigate the analgesic effect of interlaminar epidural PRP for patients with thoracic herpes zoster.

Conditions

Acute Herpes Zoster Neuropathy

Outcome Measures

Primary Outcomes (1)

• Pain score

  Pain intensity will be graded using numerical rating scale from 0 to 10 with 0 represents no pain and 10 represents the worst pain.

  on postoperative day 1

Interventions

platelet rich plasma injection BIOLOGICAL

Platelet rich plasma will be injected to the epidural space under light sedation using target-controlled infusion of propofol to an effect site concentration of between 0.5 to 1.5mcg/ml.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients attending Accident and Emergency Department, Queen Mary Hospital, Hong Kong for herpes zoster.

You may qualify if:

• Age 18 years or above
• Average numerical rating scale (NRS) pain score over 3 out of ten over the week
• Onset of herpes zoster within 2 weeks
• Thoracolumbar herpes zoster
• Able to provide informed consent

You may not qualify if:

• Cervical and trigeminal herpes zoster
• Bilateral involvement of herpes zoster
• Using anticoagulant and/or antiplatelet medication (not including aspirin)
• Allergy: contrast dye, PRP, local anaesthetic
• pregnancy

Sponsors & Collaborators

• The University of Hong Kong: lead

Study Sites (1)

The University of Hong Kong

Hong Kong, Hong Kong

RECRUITING

Central Study Contacts

Stanley SC Wong, MD, MBBS

CONTACT

22553303; wongstan@hku.hk

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Associate Professor

Study Record Dates

• First Submitted: September 8, 2022
• First Posted: September 13, 2022
• Study Start: September 1, 2022
• Primary Completion: December 31, 2023
• Study Completion: September 30, 2024
• Last Updated: May 10, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)